RxDoctor Payments Data

Royal Park, MD

Urology · Torrance, CANPI 1336192301

Payments from drug & device makers

$12,657in general payments, 2019–2025

Across 495 payments — averaging $25.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SN Holdings, LLC$2K
  • Astellas Pharma US Inc$1K
  • Dendreon Pharmaceuticals LLC$1K
  • AbbVie$948
  • Bayer$850
  • Teleflex LLC$810
  • plus $6K from 50 others

What the payments were for

  • Travel & lodging$3373%
  • Food & beverage$11,91594%
  • Education$4053%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,657 in reported general payments places this provider in the 75th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$297,414
Medicare patients
487
Services billed
4,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron132$125,181
MyrbetriqMirabegron91$88,224
OrgovyxRelugolix12$31,291
Tamsulosin Hcl1,049$16,673
Finasteride340$4,674
Testosterone16$4,147
Potassium Citrate ErPotassium Citrate27$4,002
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst129$3,797
Methenamine Hippurate17$2,554
Dutasteride98$2,476
Silodosin41$2,220
Alfuzosin Hcl ErAlfuzosin Hcl95$1,594
Estradiol25$1,469
Doxycycline Hyclate41$962
Oxybutynin Chloride ErOxybutynin Chloride65$779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$593$156,472144 claims
Astellas Pharma US IncMyrbetriq$1,221$88,22491 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,324 urology providers in California.

Other urology in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →